PMID- 26402401
OWN - NLM
STAT- MEDLINE
DCOM- 20160906
LR  - 20151110
IS  - 1473-6551 (Electronic)
IS  - 1350-7540 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec
TI  - Immunotherapy for glioblastoma: concepts and challenges.
PG  - 639-46
LID - 10.1097/WCO.0000000000000249 [doi]
AB  - PURPOSE OF REVIEW: Immunotherapy is an emerging treatment strategy against 
      various cancer types including glioblastoma. It comprises different strategies to 
      induce, boost or restore an antitumor immune response. This review provides an 
      overview of recent preclinical and clinical developments in the field of 
      immunotherapy against glioblastoma. We elucidate the concepts and challenges and 
      point out the strengths and weaknesses of the most promising immunotherapeutic 
      approaches. RECENT FINDINGS: Immunotherapy is one of the most active research 
      areas in glioblastoma. Data from preclinical work as well as phase I and phase II 
      clinical trials revealed that immunotherapy against glioblastoma is overall well 
      tolerated and able to promote a potent antitumor immune response. Among the 
      therapeutic approaches that are currently under investigation, vaccination, for 
      example, against the variant III of epidermal growth factor receptor, as well as 
      immune checkpoint inhibition targeting receptors such as cytotoxic T 
      lymphocyte-associated antigen-4 and programmed cell death-1, are among the most 
      promising and advanced treatment strategies. However, there are considerable 
      challenges to overcome such as the identification of novel target molecules for 
      vaccination, appropriate patient selection criteria, strategies to prevent or 
      handle immune-related adverse events, and the implementation of immunotherapy in 
      multimodal treatment regimens together with conventional treatment strategies. 
      SUMMARY: Key features of immunotherapy are target specificity, adaptability, and 
      durability. Results from preclinical assessments and clinical trials applying 
      immunotherapy alone or in combination with conventional treatment options are 
      promising. However, intense research and stringent clinical development are 
      required to optimize the available treatment options and to overcome potential 
      pitfalls.
FAU - Weiss, Tobias
AU  - Weiss T
AD  - Department of Neurology and Brain Tumor Center, University Hospital Zurich and 
      University of Zurich, Zurich, Switzerland.
FAU - Weller, Michael
AU  - Weller M
FAU - Roth, Patrick
AU  - Roth P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Curr Opin Neurol
JT  - Current opinion in neurology
JID - 9319162
SB  - IM
MH  - Glioblastoma/*therapy
MH  - Humans
MH  - Immunotherapy/*methods
EDAT- 2015/09/25 06:00
MHDA- 2016/09/07 06:00
CRDT- 2015/09/25 06:00
PHST- 2015/09/25 06:00 [entrez]
PHST- 2015/09/25 06:00 [pubmed]
PHST- 2016/09/07 06:00 [medline]
AID - 10.1097/WCO.0000000000000249 [doi]
PST - ppublish
SO  - Curr Opin Neurol. 2015 Dec;28(6):639-46. doi: 10.1097/WCO.0000000000000249.